750
Participants
Start Date
October 8, 2020
Primary Completion Date
August 9, 2021
Study Completion Date
January 20, 2022
Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb
Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI
Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII
Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Pneumococcal 13 - valent conjugate vaccine-Prevnar 13
Pharmaceutical form:Suspension for injection Route of administration: intramuscular
Pneumococcal Vaccine Polyvalent-Pneumovax 23
Pharmaceutical form:Solution for injection Route of administration: intramuscular
Preferred Primary Care Physicians Site Number : 8400009, Pittsburgh
Coastal Carolina Research Center - N Charleston Site Number : 8400004, North Charleston
Jacksonville Center for Clinical Research Site Number : 8400016, Jacksonville
Suncoast Research Associates, LLC Site Number : 8400017, Miami
Aventiv Research Columbus Site Number : 8400007, Columbus
Velocity Clinical Research Valparaiso Site Number : 8400001, Valparaiso
Plains Clinical Research Center, LLC Site Number : 8400011, Fargo
Be Well Clinical Studies Site Number : 8400018, Lincoln
Velocity Clinical Research Site Number : 8400005, Metairie
Paradigm Clinical Research Center Wheat Ridge Site Number : 8400002, Wheat Ridge
Advanced Clinical Research - Magic View Site Number : 8400003, Meridian
JBR Clinical Research Site Number : 8400008, Salt Lake City
WR-CRCN, LLC Site Number : 8400013, Las Vegas
Peninsula Research Associates Site Number : 8400012, Rolling Hills Estates
Emmaus Research Center, Inc Site Number : 8400014, Anaheim
Velocity Clinical Research, Medford Site Number : 8400010, Medford
Biotrial Inc Site Number : 8400006, Newark
Lead Sponsor
Sanofi
INDUSTRY